- Home
- ICE vs GKOS Comparison
ICE vs GKOS Comparison
Compare ICE & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICE
- GKOS
- Stock Information
- Founded
- ICE 2000
- GKOS 1998
- Country
- ICE United States
- GKOS United States
- Employees
- ICE N/A
- GKOS N/A
- Industry
- ICE Investment Bankers/Brokers/Service
- GKOS Medical/Dental Instruments
- Sector
- ICE Finance
- GKOS Health Care
- Exchange
- ICE Nasdaq
- GKOS Nasdaq
- Market Cap
- ICE N/A
- GKOS 5.1B
- IPO Year
- ICE 2005
- GKOS 2015
- Fundamental
- Price
- ICE $162.98
- GKOS $95.41
- Analyst Decision
- ICE Strong Buy
- GKOS Strong Buy
- Analyst Count
- ICE 16
- GKOS 13
- Target Price
- ICE $182.81
- GKOS $155.00
- AVG Volume (30 Days)
- ICE 4.2M
- GKOS 1.0M
- Earning Date
- ICE 05-01-2025
- GKOS 04-30-2025
- Dividend Yield
- ICE 1.18%
- GKOS N/A
- EPS Growth
- ICE 14.08
- GKOS N/A
- EPS
- ICE 4.78
- GKOS N/A
- Revenue
- ICE $9,279,000,000.00
- GKOS $383,481,000.00
- Revenue This Year
- ICE $7.01
- GKOS $27.84
- Revenue Next Year
- ICE $6.14
- GKOS $27.99
- P/E Ratio
- ICE $34.10
- GKOS N/A
- Revenue Growth
- ICE 16.16
- GKOS 21.85
- 52 Week Low
- ICE $124.34
- GKOS $77.91
- 52 Week High
- ICE $177.45
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- ICE 50.23
- GKOS 48.65
- Support Level
- ICE $153.13
- GKOS $87.17
- Resistance Level
- ICE $160.81
- GKOS $98.86
- Average True Range (ATR)
- ICE 5.50
- GKOS 5.88
- MACD
- ICE 0.44
- GKOS 1.55
- Stochastic Oscillator
- ICE 81.68
- GKOS 83.53
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.